Compugen Ltd.
CGENNASDAQHealthcare● Active
$2.04
$-0.06(-2.86%)
Market Cap$192888528
P/E Ratio—
52W High$3.24
52W Low$1.3
Compugen Ltd. (CGEN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CGEN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 18, 2026EPS Actual
-$0.08
Est. -$0.07 · -14.3%
Revenue
$0.00B
Est. $0.00B · +38.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 18, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
CGEN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.07 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 18, 2026 | -$0.07 | -$0.08 | -14.3% | $0.00B | $0.00B | +38.5% |
| ▲ Q1 FY2026 | Mar 2, 2026 | -$0.07 | $0.60 | +957.1% | $0.07B | $0.00B | +3018.2% |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.09 | -$0.07 | +22.2% | $0.00B | $0.01B | -86.8% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.07 | -$0.08 | -14.3% | $0.00B | $0.00B | -14.4% |
| ▼ Q2 FY2025 | May 19, 2025 | -$0.06 | -$0.08 | -33.3% | $0.00B | $0.00B | -38.3% |
| ▼ Q1 FY2025 | Mar 4, 2025 | $0.07 | -$0.07 | -200.0% | $0.00B | $0.01B | -70.6% |
| ▼ Q4 FY2024 | Nov 12, 2024 | $0.06 | $0.01 | -83.3% | $0.02B | $0.02B | -4.1% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.07
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 18, 2026Miss
EPS Actual
-$0.08
EPS Est.
-$0.07
EPS Surpr.
-14.3%
Revenue
$0.00B
Q1 FY2026
Mar 2, 2026Beat
EPS Actual
$0.60
EPS Est.
-$0.07
EPS Surpr.
+957.1%
Revenue
$0.07B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.09
EPS Surpr.
+22.2%
Revenue
$0.00B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$0.08
EPS Est.
-$0.07
EPS Surpr.
-14.3%
Revenue
$0.00B
Q2 FY2025
May 19, 2025Miss
EPS Actual
-$0.08
EPS Est.
-$0.06
EPS Surpr.
-33.3%
Revenue
$0.00B
Q1 FY2025
Mar 4, 2025Miss
EPS Actual
-$0.07
EPS Est.
$0.07
EPS Surpr.
-200.0%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
$0.01
EPS Est.
$0.06
EPS Surpr.
-83.3%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.12 | $-0.11 | $-0.10 | 1 |
| Q3 FY2027 | $-0.12 | $-0.11 | $-0.09 | 1 |
| Q2 FY2027 | $-0.10 | $-0.09 | $-0.08 | 1 |
| Q1 FY2027 | $-0.10 | $-0.09 | $-0.08 | 1 |
| Q4 FY2026 | $-0.05 | $-0.05 | $-0.04 | 1 |
| Q3 FY2026 | $-0.10 | $-0.08 | $-0.06 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 18, 2026 | -14.3% | $2.75 | $2.86 | +4.00% |
| ▲ Q1 FY2026 | Mar 2, 2026 | +957.1% | $1.81 | $2.25 | +24.31% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +22.2% | $1.62 | $1.67 | +3.09% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -14.3% | $1.46 | $1.46 | +0.00% |
| ▼ Q2 FY2025 | May 19, 2025 | -33.3% | $1.39 | $1.39 | +0.00% |
| ▼ Q1 FY2025 | Mar 4, 2025 | -200.0% | $1.81 | $1.68 | -7.18% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -83.3% | $1.74 | $1.60 | -8.05% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +75.0% | $1.64 | $1.72 | +4.88% |
Q2 FY2026+4.00%
Report Date
May 18, 2026
EPS Beat/Miss
-14.3%
Price Before
$2.75
Price After
$2.86
Q1 FY2026+24.31%
Report Date
Mar 2, 2026
EPS Beat/Miss
+957.1%
Price Before
$1.81
Price After
$2.25
Q4 FY2025+3.09%
Report Date
Nov 10, 2025
EPS Beat/Miss
+22.2%
Price Before
$1.62
Price After
$1.67
Q3 FY2025+0.00%
Report Date
Aug 6, 2025
EPS Beat/Miss
-14.3%
Price Before
$1.46
Price After
$1.46
Q2 FY2025+0.00%
Report Date
May 19, 2025
EPS Beat/Miss
-33.3%
Price Before
$1.39
Price After
$1.39
Q1 FY2025-7.18%
Report Date
Mar 4, 2025
EPS Beat/Miss
-200.0%
Price Before
$1.81
Price After
$1.68
Q4 FY2024-8.05%
Report Date
Nov 12, 2024
EPS Beat/Miss
-83.3%
Price Before
$1.74
Price After
$1.60
Q3 FY2024+4.88%
Report Date
Aug 6, 2024
EPS Beat/Miss
+75.0%
Price Before
$1.64
Price After
$1.72
Avg Beat Reaction+10.76%
Avg Miss Reaction-2.25%
Beat Rate3 / 8 quarters
Largest Move+24.31% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CGEN ends December
Compugen Ltd. (CGEN) most recently reported earnings on May 18, 2026 for Q2 FY2026, posting EPS of $-0.08 — missing the analyst consensus of $-0.07 by -14.3%. The next CGEN earnings date is expected around September 1, 2026.
Each quarter, investors track CGEN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CGEN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CGEN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CGEN earnings · 5 questionsCompugen Ltd.'s next earnings report is expected around September 1, 2026. CGEN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CGEN historically reports after market close (AMC).
CGEN earnings datewhen is CGEN earningsCGEN next earnings datewhen does CGEN report earningsCGEN earnings calendar
▸ Source: FMP · Compugen Ltd. SEC filings · US GAAP · Compugen Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026